Tag Archive for: Ingrezza

Neurocrine wins FDA approval for ‘sprinkle’ formulation of Ingrezza for Huntington’s disease

Neurocrine Biosciences won the FDA’s approval for a sprinkle capsule formulation of Ingrezza, providing a more convenient route of treatment for Huntington’s disease patients with trouble swallowing.

Read more
/by

Neurocrine posts positive Phase III Huntington’s data for Ingrezza, touts 29% YoY growth

,

In a late-stage study, most Huntington’s disease patients reported that their symptoms of chorea were “much improved” or “very much improved” following treatment with Neurocrine Biosciences’ VMAT2 inhibitor Ingrezza.

Read more
/by